💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, trading cheap versus its own history — but flagged on governance.
AstraZeneca Pharma Ind is scored on the pharma / healthcare framework. It keeps a slim 8.1% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -0.08×) — worth a closer look. Free cash flow is worth about 0.0% of its market value.
Over the last 3 years revenue compounded at 31%/yr and profit at 24%/yr. Book value has grown 14%/yr. Return on equity is an elite 20.2%. In the latest quarter profit fell 15% versus the prior quarter.
At 85× earnings, the stock sits at the 11th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~30%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: Only ₹0.24 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 94.15 | — | — |
| P/B | 18.3 | 4.11 | worse |
| EV/EBITDA | 56.84 | 19.15 | worse |
| ROE | 20.22 | — | — |
| ROCE | 25.24 | 6.87 | better |
| ROA | 8.11 | — | — |
| Quick Ratio | 0.73 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 31% CAGR over 3 years — high-growth territory.
Revenue is outpacing profit (31% vs 24%) — costs are rising faster than the top line. The latest year saw a +62% swing — check if it's a one-off or structural.
Operating margin has compressed from 13% to 11% — costs or competition are eating into profitability.
ROE at 21% — the business earns well above its cost of equity.
24% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 18% sequentially — momentum is building. Run-rate stepping up — recent quarters average 8% above earlier ones.
Profit fell 15% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (10% → 5%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 75.0% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.